Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03789578
Recruitment Status : Completed
First Posted : December 28, 2018
Last Update Posted : October 23, 2019
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when given alone or together. Participants will get 3 study medicines at 3 different time points: 1) a combination of semaglutide plus insulin 287, 2) insulin 287 alone and 3) semaglutide alone. The order in which participants get them is decided by chance. Participants will get all medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks. The study will last for about 19 to 32 weeks in total.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: NNC0148-0287sema Drug: Semaglutide Drug: NNC0148-0287 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This is a three-period cross-over trial. The treatments to be used are: Treatment A: insulin 287, Treatment B: semaglutide, and Treatment C: NNC0148-0287sema. The subjects will be randomised to one of the six treatment sequences in the trial: 1) ABC, 2) ACB, 3) BAC, 4) BCA, 5) CAB, and 6) CBA. The trial includes a screening visit followed by three 5 -week periods with pharmacokinetic sampling after single dose administration. The dose periods are separated by a 1-4 week washout period (from last pharmacokinetic sampling to next dosing). The follow-up period is 1−4 weeks after last pharmacokinetic sampling in period 3 (i.e. 6 to 9 weeks after last trial product administration). The total trial duration for the individual subjects participating in the trial will be 19 to 32 weeks (including follow-up), depending on individual visit schedules.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Primary Purpose: Treatment
Official Title: A Trial to Investigate Single Dose Pharmacokinetics of NNC0148-0287sema in a Fixed Ratio Compared With Insulin 287 and Semaglutide Given Separately in Subjects With Type 2 Diabetes
Actual Study Start Date : January 17, 2019
Actual Primary Completion Date : October 10, 2019
Actual Study Completion Date : October 10, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Semaglutide plus insulin 287
Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
Drug: NNC0148-0287sema
Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.

Experimental: Semaglutide alone
Participants will get a single dose of semaglutide (treatment B) alone.
Drug: Semaglutide
Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Other Name: Ozempic®

Experimental: Insulin 287 alone
Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
Drug: NNC0148-0287
Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.




Primary Outcome Measures :
  1. AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

  2. AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.


Secondary Outcome Measures :
  1. AUCI287,0-∞ area under the serum insulin 287 concentration-time curve from 0 hours to infinity after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

  2. Cmax, I287, maximum observed serum insulin 287 concentration after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

  3. tmax, I287, time to maximum observed serum insulin 287 concentration after a single dose [ Time Frame: 0-840 hours ]
    Measured in hour (h) for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

  4. AUCSema,0-∞, area under the plasma semaglutide concentration-time curve from 0 hours to infinity after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

  5. Cmax,Sema, maximum observed plasma semaglutide concentration after a single dose [ Time Frame: 0-840 hours ]
    Measured in pmol/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

  6. tmax,Sema, time to maximum observed plasma semaglutide concentration after a single dose [ Time Frame: 0-840 hours ]
    Measured in hour (h) for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

  7. Number of treatment emergent adverse events [ Time Frame: Day 1 (beginning of each period) to day 36 (end of each period) ]
    Count of events.

  8. Number of hypoglycaemic episodes [ Time Frame: Day 1 (beginning of each period) to day 36 (end of each period) ]
    Count of episodes.

  9. Antibodies for insulin 287: Change in anti-insulin 287 binding antibody levels [ Time Frame: Day -1 (pre-dose), Day 36 (end of period) ]
    Measured as percentage B/T following administration of NNC0148 -0287sema and insulin 287.

  10. Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies [ Time Frame: Day 36 (end of period) ]
    Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.

  11. Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin [ Time Frame: Day 36 (end of period) ]
    Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.

  12. Antibodies for semaglutide: Change in anti-semaglutide binding antibody levels [ Time Frame: Day -1 (pre-dose), Day 36 (end of period) ]
    Measured as percentage B/T following administration of NNC0148 -0287sema

  13. Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies [ Time Frame: Day 36 (end of period) ]
    Percentage of events (yes/no) following administration of NNC0148 -0287sema.

  14. Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous glucagon-like peptide-1 (GLP-1) [ Time Frame: Day 36 (end of period) ]
    Percentage of events (yes/no) following administration of NNC0148 -0287sema.

  15. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-semaglutide binding antibody levels [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Measured as percentage B/T.

  16. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous GLP-1 [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Percentage of events (yes/no).

  17. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-insulin 287 binding antibody levels [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Measured as percentage B/T.

  18. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Percentage of events (yes/no).

  19. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Percentage of events (yes/no).

  20. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1 [ Time Frame: Day 151 (follow-up/end-of-trial visit) ]
    Percentage of events (yes/no).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus more than or equal to 180 days prior to the day of screening
  • Body weight between 80.0 to 120.0 kg (both inclusive)
  • Glycosylated haemoglobin (HbA1c) 6.0 to 8.5% (both inclusive)
  • No current and no regular previous intake of insulin. Previous insulin treatment for short periods of time (a maximum of 14 days) is allowed, as well as insulin use during a previous period of gestational diabetes in the past (as declared by the subject or reported in the medical records)
  • Stable daily dose(s) of the following anti-diabetic drug(s)/regimen within the past 90 days prior to the day of screening: a) Any metformin formulation (dose as documented in the subject medical record), b) One other oral antidiabetic drug (dose as documented in the subject medical record) is allowed, but not mandatory: Insulin secretagogue (sulphonylureas), dipeptidyl peptidase 4 (DPP-4) inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor

Exclusion Criteria:

  • Known or suspected hypersensitivity to trial products or related products
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
  • Receipt of any investigational medicinal product within 90 days before screening
  • History of severe allergies to drugs or foods or a history of severe anaphylactic reaction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03789578


Locations
Layout table for location information
Germany
Novo Nordisk Investigational Site
Neuss, Germany, 41460
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S

Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT03789578     History of Changes
Other Study ID Numbers: NN1535-4359
U1111-1204-8233 ( Other Identifier: World Health Organization (WHO) )
2017-004538-27 ( Registry Identifier: European Medicines Agency (EudraCT) )
First Posted: December 28, 2018    Key Record Dates
Last Update Posted: October 23, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
URL: https://www.novonordisk-trials.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs